Piper Sandler raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $11 from $9 and keeps an Overweight rating on the shares. The firm notes Amneal reported Q3 adjusted diluted EPS of 16c on revenue of $702M, compared to Street estimates of 13c and $694M, respectively. The company reiterated 2024 total revenue and adjusted EBITDA guidance ranges of $2.7B-$2.8B and $610M-$630M, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals Reports Q3 2024 Financial Results
- Amneal Pharmaceuticals reports Q3 adjusted EPS 16c, consensus 13c
- Amneal Pharmaceuticals backs FY24 adjusted EPS view 57c-63c, consensus 60c
- AMRX Earnings this Week: How Will it Perform?
- Amneal Pharmaceuticals receives FDA approval of Pyridostigmine Bromide NDA